CLINUVEL posts tenth consecutive profit as cash hits A$252m
CLINUVEL Pharmaceuticals has reported its tenth consecutive annual profit, closing the financial year ended 30 June 2026 with net profit after tax of A$33.9 million, down 6% on the prior year. Cash reserves climbed 12% to A$252.1 million, underpinning what the company is framing as a platform for North American growth.
Revenue from ordinary activities edged down 1% to A$94.0 million, while total revenues including interest and other income fell 4% to A$101.2 million. Operating expenses also contracted marginally to A$53.5 million, yielding a net profit before tax of A$47.7 million. The company noted that the headline profit decline was largely an accounting effect: unrealised foreign currency losses on US dollar term deposits reduced pre-tax profit by approximately A$4 million. Stripping that out, the underlying trading performance was described as stable.
Group Chief Financial Officer Peter Vaughan attributed the result to tight cost discipline. "We delivered record SCENESSE treatment volumes to EPP patients and total revenues in excess of $100 million for the second year in a row," he said. "Expenditures were tightly controlled to ensure every dollar deployed contributed to our core strategic objectives."
Revenue mix and product dynamics
CLINUVEL's lead product, SCENESSE (afamelanotide 16mg), remains the only approved systemic photoprotective therapy for adult patients with erythropoietic protoporphyria, a rare inherited metabolic disorder causing severe photosensitivity. European revenue growth offset a softer US performance, which the company attributed to two factors: competitors offering free drug to EPP patients and a shift by US Specialty Centres away from holding inventory towards just-in-time ordering. Both dynamics compressed recorded US volumes without necessarily reflecting a fall in underlying patient demand.
The Board has declared a fully franked annual dividend of A$0.05 per ordinary share, payable on 18 September 2026 to shareholders on the register at 4 September. This marks the ninth consecutive annual dividend and returns approximately 9% of FY2026 free cash generation to shareholders, an unusual feature for a company of CLINUVEL's size in the rare-disease segment.
US expansion and pipeline context
CLINUVEL is dual-listed on the ASX and Nasdaq and is actively building its US commercial and capital-markets presence. The A$252 million cash pile, which the company notes would have reached A$264 million absent a A$12.2 million income tax prepayment, is intended to self-fund that expansion without recourse to dilutive equity raises.
Beyond EPP, CLINUVEL is advancing a Phase 3 programme in vitiligo, a much larger addressable market than the ultra-rare EPP population. If that trial delivers positive data, CLINUVEL would be competing in a space already attracting significant pharmaceutical interest, with approved topical JAK inhibitors having reshaped expectations for vitiligo therapy in recent years. An approval in that indication would mark a material step change in the company's commercial scale.
The ten-year revenue compound annual growth rate of 31%, alongside an expense CAGR of 18%, illustrates the operating leverage the company has built since SCENESSE's first commercial sales. Whether that leverage extends to a new indication at meaningful scale is the central question for investors watching the vitiligo readout.